OASIS trials: establishing effective doses Phase 2 OASIS 1 findings: Tested multiple dose levels: 0.3mg, 0.6mg, 1.2mg, 2.4mg, 4.5mg weekly Duration: 26 weeks Primary endpoint: Weight loss at each dose Dose-response results: 0.3mg weekly: ~4% body weight loss 0.6mg weekly: ~6% body weight loss 1.2mg weekly: ~8% body weight loss 2.4mg weekly: ~10% body weight loss 4.5mg weekly: ~12% body weight loss Key insight: Clear dose-response relationship
Pharmaceutical-grade diluent: All products in this collection are medical-grade sterile water intended exclusively for licensed professional use in medication preparation, not for consumer or non-clinical applications
The Ethics Committee approved the study (No
Given that most clinical MRI scans operate at 3.0 T at present, and the fact that nine out of thirteen studies reviewed measured Glx, we elected to study Glx for this review
Second, both the up- and down-regulation of tyrosinase could cause the potential side effects, including complications like Parkinsons disease
